Loading…
← CockpitCompetitor Analysis › 688389.SS Shenzhen Lifotronic Technology Co., Ltd. Class AOpen in the cockpit ↗

Shenzhen Lifotronic Technology Co., Ltd. Class A688389.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum leader 80
Mkt cap
$692M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$6.51M
20-day average traded
Fwd P/E
29.9×
forward earnings
ROIC−WACC
+4.1 pp
WACC 8.6%
Hurdle
-2 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥10.78
1D-1.6%
1W-7.0%
1M-2.4%
3M-4.6%
6M-13.6%
YTD-16.9%
1Y-22.0%
ATR %3.5%
52w lowhigh26.0% off high

What Shenzhen Lifotronic Technology does

Employees: 1,756

Shenzhen Lifotronic Technology at a glance

Size Shenzhen Lifotronic Technology (688389.SS) is a China Health Care company (Medical Specialties) with a market value of $692M, the 2922nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.78 on 18 Nov 2026.

Performance Over six months the shares fell 13.6%, against -13.9% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 14.2% over the last twelve months (peer median +15.8%); the operating margin is 13.0% (peer median 15.6%).

Valuation It trades at 29.9× forward earnings against a peer median of 20.5× (5th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -2 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.1 points above its cost of capital (8.6% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 88688389.SS 87
Six months, rebased to 100: Shenzhen Lifotronic Technology against the median of its 20 peers (local-currency closes).

Shenzhen Lifotronic Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.20BCN¥1.03BCN¥1.14BCN¥1.14BCN¥976M
Revenue growth—-10%0%+16%—
Gross profitCN¥765MCN¥622MCN¥737MCN¥696MCN¥555M
EBITDAn/aCN¥183MCN¥357MCN¥321MCN¥222M
Net incomeCN¥136MCN¥184MCN¥345MCN¥329MCN¥251M
Free cash flowCN¥182MCN¥201MCN¥230MCN¥255MCN¥88.9M
Capital expenditureCN¥97.6MCN¥83.4MCN¥62.0MCN¥48.6MCN¥184M
Total debtCN¥412MCN¥398MCN¥600MCN¥243MCN¥133M

Quarterly statements and history in the cockpit →

Shenzhen Lifotronic Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%688085491000301234DCTH15017575002876688410300622301122300326SNTQDEL688179301367600855INMD603108300453688389.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen Lifotronic Technology is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×200×688085DCTH15017575002876688410300622301122300326QDEL6031081789688389.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen Lifotronic Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%688085301234DCTH15017575002876688410300326SNTINMD688389.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shenzhen Lifotronic Technology is the large dot.

Shenzhen Lifotronic Technology competitors and peer comparison

How Shenzhen Lifotronic Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen Lifotronic Technology against its 20 peers (data as of 18 Nov 2026)
Measure688389.SSPeer medianRank in peer set
1-month return-2.4%-8.9%8th highest of 21
6-month return-13.6%-13.9%11th highest of 21
Distance from 52-week high-26.0%-35.5%9th highest of 21
Revenue growth (TTM)+14.2%+15.8%10th lowest of 21
Operating margin13.0%15.6%10th lowest of 21
Forward P/E29.9×20.5×5th most expensive of 18
Growth the price implies (Req g, 7 yrs)11.6%3.4%7th most demanding of 17
Growth delivered (Del g)+13.3%+13.3%9th highest of 17
Hurdle (Req g minus delivered)-1.7 pp-13.0 pp5th most demanding of 17
ROIC minus cost of capital+4.1 pp+3.8 pp11th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%29.9×11.6%+13.3%
Shanghai Sanyou Medical 688085.SSChina$692M-23%+15%4%50.0×29.0%+6.8%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%n/an/an/a
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%n/a31.8%-0.6%
Delcath Systems DCTHUnited States$685M+75%+38%5%358.9×33.4%+120.2%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%

Questions

Which companies are Shenzhen Lifotronic Technology's closest peers?
The cockpit's peer set: Shanghai Sanyou Medical (688085.SS), Livsmed (491000.KS), Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ), Delcath Systems (DCTH), Shanghai INT Medical Instruments (1501.HK), Japan Lifeline (7575.T), Shenzhen Sunnypol Optoelectornics (002876.SZ), SWS Hemodialysis Care (688410.SS).
Is Shenzhen Lifotronic Technology expensive compared with its peers?
On forward p/e it trades at 29.9× against a peer median of 20.5×, 5th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has Shenzhen Lifotronic Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -13.6% against -13.9% for the median peer; over one year -22.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.